Abstract:Abstract Single-cell sequencing techniques have greatly advanced our current understanding of intratumoral heterogeneity through identifying tumor subpopulations with distinct biologies and therapeutic responses. However, translating biological differences into treatment strategies is challenging, as we still lack tools to facilitate efficient drug discovery that tackles heterogeneous tumors. One key step in development of such approaches centers around accurate prediction of drug response at the single-cell level to offer therapeutic options to specific cell subpopulations. Here, we present a transparent computational framework (nicknamed scIDUC) to predict therapeutic efficacies on an individual-cell basis by integrating single-cell transcriptomic profiles with large, data-rich pan-cancer cell line screening datasets. Our method detects shared expression patterns between the two data sources and utilizes such information to project cellular drug response. This method achieves high accuracy, with predicted sensitivities easily able to separate cells into their true cellular drug resistance status as measured by effect size (Cohen's d > 1.0); this holds when using single-cell RNA-seq from both cell line and in vivo models. More importantly, we examine our method’s utility with three distinct prospective tests, and in each our predicted results are accurate and mirrored biological expectations. In the first two tests, we investigated predicting drugs for cell subpopulations that are resistant to standard-of-care (SOC) therapies due to intrinsic resistance or effects of tumor microenvironments. In both, our results showed high consistency with results from the original studies. In the third test, we generated SOC therapy resistant cell lines, used scIDUC to identify drugs predicted effective on the resistant line, and validated the predictions with in vitro experiments. Together, scIDUC quickly and directly translates scRNA-seq data into meaningful cellular drug response for individual cells, displaying the potential to be used by researchers as a first-line tool for nuanced and heterogeneity-aware drug discovery. Citation Format: Weijie Zhang, Danielle Maeser, Adam Lee, Yingbo Huang, Robert F Gruener, Sampreeti Jena, Anand G Patel, R. Stephanie Huang. Inferring therapeutic vulnerability within tumors through integration of pan-cancer cell line and single-cell transcriptomic profiles [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr A136.

Deciphering single-cell gene expression variability and its role in drug response

Scrank Infers Drug-Responsive Cell Types from Untreated Scrna-Seq Data Using a Target-Perturbed Gene Regulatory Network

Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

scPharm: identifying pharmacological subpopulations of single cells for precision medicine in cancers

State-of-the-Art Technologies to Interrogate Genetic/Genomic Components of Drug Response

Genetic variants associated with cell-type-specific intra-individual gene expression variability reveal new mechanisms of genome regulation

Estimating the impact of single-cell RNA sequencing of human tissues on drug target validation.

Deciphering Genetic Influence on Drug Response

scDR: Predicting Drug Response at Single-Cell Resolution

Applications of single-cell RNA sequencing in drug discovery and development

Modeling Expression Plasticity of Genes That Differentiate Drug-Sensitive from Drug-Resistant Cells to Chemotherapeutic Treatment

Enabling Single‐Cell Drug Response Annotations from Bulk RNA‐Seq Using SCAD

Pharmacogenomics Signature: A Novel Strategy on the Individual Differences in Drug Response.

Abstract A136: Inferring therapeutic vulnerability within tumors through integration of pan-cancer cell line and single-cell transcriptomic profiles

Characterization of Expression-Based Gene Clusters Gives Insights into Variation in Patient Response to Cancer Therapies

scDrug+: predicting drug-responses using single-cell transcriptomics and molecular structure

Single-cell transcriptomics unveils gene regulatory network plasticity

Achieving a Deeper Understanding of Drug Metabolism and Responses Using Single-Cell Technologies

Deciphering cell-cell interactions and communication in the tumor microenvironment and unraveling intratumoral genetic heterogeneity via single-cell genomic sequencing

Characterizing the genetic architecture of drug response using gene-context interaction methods

Functional phenotyping of genomic variants using multiomic scDNA-scRNA-seq